Home / Pinealon Research Guide
Research GuideNeuroprotectiveLongevity

Pinealon:
The Neuroprotective Pineal Peptide

A tripeptide (EDR) from the pineal gland that crosses the blood-brain barrier, reduces neuronal oxidative damage, and modulates CLOCK gene expression — the CNS-focused member of the Epithalon peptide family.

10 min read
🧠 CNS focus
📅 Updated April 2026
3
Amino Acids
BBB
Blood-Brain Barrier Penetrating
10–20 days
Typical Cycle
Jump toWhat Is ItMechanismResearchProtocolvs EpithalonFAQ
The Basics

What Is Pinealon?

Pinealon is a synthetic tripeptide — Glu-Asp-Arg (EDR) — developed by the St. Petersburg Institute of Bioregulation and Gerontology as part of a broader research program into short regulatory peptides derived from the pineal gland. It's part of the same family as Epithalon (AEDG), Cortagen, and Vilon — cytomedins developed by Vladimir Khavinson and colleagues beginning in the 1980s as tissue-specific bioregulators.

Unlike Epithalon, which is derived from the epithalamin protein and targets telomerase activation, Pinealon is specifically studied for its effects on the central nervous system — particularly neuroprotection, cognitive function, and circadian rhythm regulation. It's the neurological member of the pineal gland peptide family.

Russian Research Origin

Like Semax, Selank, and Epithalon, Pinealon originates from Russian peptide research with a significant body of literature in Russian-language journals. The research is legitimate and substantial but less integrated into mainstream Western literature than American or European peptide research. This context matters when evaluating the evidence base.

3
Amino Acids (EDR)
CNS
Primary Target
SubQ / Nasal
Routes
Pineal gland
Origin tissue
Mechanism

How Does Pinealon Work?

Pinealon's mechanism centers on its ability to penetrate the blood-brain barrier — a significant advantage for a small tripeptide — and interact directly with neuronal DNA and chromatin. The Khavinson group's research proposes that short regulatory peptides like Pinealon act as epigenetic regulators, binding to specific promoter sequences and modulating gene expression in target tissues.

In neuronal cell models, Pinealon has been shown to influence expression of genes involved in:

Epigenetic Regulatory Model

The mechanism proposed for Pinealon — short peptide binding to DNA promoter regions to regulate gene expression — is the same framework applied to Epithalon and the broader Khavinson peptide family. It's a compelling model with supporting in vitro data, though the full mechanistic picture in living systems is still being characterized.

Research Data

What the Research Shows

Neuroprotection Under Oxidative Stress

The most consistent Pinealon findings come from neuronal cell culture and animal models of oxidative stress. Studies by Khavinson, Linkova, and colleagues have shown that Pinealon pretreatment significantly reduces neuronal cell death following oxidative challenge — with measurable reductions in ROS accumulation, lipid peroxidation markers, and caspase-3 activation in treated cells versus controls.

Aged Animal Models

In aged rodent models, Pinealon administration has been associated with improvements in learning and memory task performance, reduced oxidative damage markers in brain tissue, and improved antioxidant enzyme activity. The effect size is modest but consistent across multiple research groups working within the Khavinson framework.

Hypoxia and Ischemia Models

Several studies have examined Pinealon in hypoxic and ischemic neuronal models — conditions relevant to stroke and traumatic brain injury research. Pinealon pretreatment reduced cell death and preserved mitochondrial membrane potential in neurons subjected to oxygen deprivation, suggesting neuroprotective effects under acute injury conditions.

Circadian Rhythm Research

Given Pinealon's pineal gland origin and interaction with CLOCK gene expression, a subset of research has examined its effects on biological rhythm regulation. This remains a less developed area of the literature but connects Pinealon to the broader melatonin/pineal axis research context.

Research Quality Context

Most Pinealon research comes from the St. Petersburg group that developed the compound. Independent replication by unaffiliated research groups is limited — a meaningful caveat when evaluating the strength of the evidence. The mechanistic framework is coherent and in vitro data is supportive, but the research base is thinner and less independently verified than for compounds like BPC-157 or Sermorelin.

Protocol Data

Dosage & Administration

Pinealon dosing is less standardized than compounds with larger independent research bases. Protocols are extrapolated from the Khavinson group's published work and research community practice.

RouteDoseFrequencyDuration
Subcutaneous5–10mg/dayDaily10–20 days per cycle
Intranasal1–2mg/dayDaily10–20 days per cycle

The Khavinson peptide family is typically used in defined short cycles (10–20 days) rather than continuous long-term administration, with breaks of several weeks between cycles. This contrasts with some other peptides that run for months continuously.

Stacking With Epithalon

Pinealon and Epithalon are frequently combined in longevity-focused research protocols. The rationale: Epithalon targets telomerase and telomere maintenance (cellular aging at the chromosomal level); Pinealon targets neuroprotection and CNS function. Both are pineal-derived short peptides with complementary applications — one systemic longevity, one neurological protection. The combination is common in the Russian peptide research tradition and has been adopted by the broader research community.

Reconstitution

Pinealon typically comes as a lyophilized powder in 20mg vials. Reconstitute with 2mL bacteriostatic water for a 10mg/mL concentration. At a 5mg dose, that's 0.5mL (50 units on a U100 syringe). Store reconstituted solution refrigerated and use within 30 days.

Comparison

Pinealon vs Epithalon

Both peptides come from the same research tradition and the same source tissue, but they have distinct targets and research profiles:

FactorPinealonEpithalon
SequenceGlu-Asp-Arg (EDR)Ala-Glu-Asp-Gly (AEDG)
Primary research focusNeuroprotection, CNS, circadianTelomerase activation, longevity
Key mechanismNeuronal antioxidant, apoptosis regulationTelomerase stimulation, epigenetic normalization
Target tissue emphasisBrain / CNSBroad systemic / cellular aging
Research originKhavinson group, St. PetersburgKhavinson group, St. Petersburg
Research volumeModerateMore extensive
Typical cycle10–20 days10–20 days
Common useOften stacked with EpithalonStandalone or stacked with Pinealon

View Pinealon Pricing & Vendor Data

COA-verified vendor pricing with promo codes. Tegridy Research currently carries Pinealon.

View Pricing → Dosage Calculator
Common Questions

FAQ

Is Pinealon the same as Epitalon / Epithalon?
No — they're different peptides from the same research group and tissue origin. Epithalon (AEDG) is a tetrapeptide focused on telomerase activation and is the more widely known of the two. Pinealon (EDR) is a tripeptide with a more specific CNS and neuroprotective focus. They're often used together precisely because they address different aspects of aging biology.
Why are Pinealon cycles so short (10–20 days)?
The short-cycle protocol is characteristic of the Khavinson peptide research tradition. The hypothesis is that these short regulatory peptides work by resetting or normalizing gene expression patterns, and that prolonged continuous exposure is neither necessary nor optimal — the gene expression changes persist after the peptide is cleared. Whether this model is correct is debated, but the short-cycle approach is the norm for this peptide family in both research and practice.
Can Pinealon be used intranasally?
Yes — intranasal delivery is used in some research protocols given Pinealon's CNS targeting. The nasal route provides a path that partially bypasses the blood-brain barrier via olfactory nerve pathways, potentially improving CNS delivery compared to SubQ injection. Doses used intranasally are lower (1–2mg vs 5–10mg SubQ) to account for the more direct CNS delivery route.
How does Pinealon relate to melatonin research?
Pinealon originates from the pineal gland — the same structure that produces melatonin. While Pinealon doesn't directly modulate melatonin synthesis or the melatonin receptor pathway, it shares the broader research context of pineal gland biology and circadian rhythm regulation. Some researchers pair Pinealon with melatonin supplementation in protocols targeting circadian rhythm restoration in aged subjects, though direct interaction data is limited.
Research purposes only. Pinealon is a research compound. This content is for educational reference only and does not constitute medical advice.
Keep Reading

Related Articles